Wolverine Asset Management LLC Trims Holdings in Amedisys, Inc. (NASDAQ:AMED)

Wolverine Asset Management LLC trimmed its position in Amedisys, Inc. (NASDAQ:AMED) by 59.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,966 shares of the health services provider’s stock after selling 20,815 shares during the quarter. Wolverine Asset Management LLC’s holdings in Amedisys were worth $1,268,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. National Bank of Canada FI raised its stake in shares of Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock worth $5,365,000 after purchasing an additional 30,213 shares during the last quarter. ABC Arbitrage SA purchased a new position in shares of Amedisys in the fourth quarter worth about $2,522,000. Geode Capital Management LLC grew its holdings in Amedisys by 1.3% during the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after acquiring an additional 7,071 shares during the period. Quarry LP acquired a new stake in Amedisys during the third quarter worth about $2,569,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Amedisys by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock worth $33,400,000 after acquiring an additional 9,004 shares during the period. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Stock Down 0.7 %

Amedisys stock opened at $90.43 on Friday. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of 35.88, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The business’s 50-day moving average price is $90.74 and its 200 day moving average price is $93.40. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Wall Street Analyst Weigh In

Separately, Stephens reaffirmed an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a report on Wednesday, February 12th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.